Loading…
← CockpitCompetitor Analysis › IONS Ionis Pharmaceuticals, Inc.Open in the cockpit ↗

Ionis Pharmaceuticals, Inc.IONSCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Pioneer of antisense-oligonucleotide drugs, selling Tryngolza and Wainua and earning royalties on partnered medicines.

Momentum laggard 4
Mkt cap
$4.56B
US dollars, full cap
Free float
98%
of shares outstanding
$/day
$163M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-72.1 pp
WACC 6.7%
Hurdle
n/a
no reverse DCF
Next earnings
98 days
24 Feb 2027
Close · USD$27.39
1D+1.6%
1W-3.3%
1M-39.7%
3M-53.4%
6M-63.5%
YTD-65.4%
1Y-62.6%
ATR %8.0%
Beta0.43
52w lowhigh68.4% off high

What Ionis Pharmaceuticals does

Pioneer of antisense-oligonucleotide drugs, selling Tryngolza and Wainua and earning royalties on partnered medicines.

Partners have long paid it upfront licence fees, milestone payments and royalties, which funded the business until its own medicines launched. It now sells Tryngolza itself and shares Wainua with AstraZeneca, so product sales are only starting to become a main income line.

Products and services

  • Tryngolza (severe hypertriglyceridemia)
  • Wainua (ATTR amyloidosis)
  • Spinraza royalties (with Biogen)

Customers

  • Cardiologists/lipid specialists
  • Neurologists
  • Payers

Where it sits in the supply chain

  • Pharmaceuticals
  • Biotech
  • Antisense/RNA-targeted therapeutics

What could go right

  • Newly launched Tryngolza/Wainua ramping revenue
  • Partner royalty and milestone income

What could go wrong

  • Transition costs building an independent sales force
  • Competition from RNAi (Alnylam) in overlapping indications

Moat: narrow (IP / patents, process know-how). Deep antisense-chemistry patent estate and decades of manufacturing know-how license out to multiple partners.

Headquarters: Carlsbad, California, United States · Founded: 1989 · Employees: 1,402

Named competitors

Ionis Pharmaceuticals at a glance

Size Ionis Pharmaceuticals (IONS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $4.56B, the 1242nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $27.39 on 18 Nov 2026.

Performance Over six months the shares fell 63.5%, against +10.4% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue fell 0.8% over the last twelve months (peer median +12.0%); the operating margin is -58.9% (peer median 15.8%).

Valuation It trades at 5.0× enterprise value to sales against a peer median of 4.5× (8th most expensive of 18).

Capital Return on invested capital runs 72.1 points below its cost of capital (6.7% WACC).

Credit Ionis Pharmaceuticals has 2 bonds outstanding ($1.34B).

Short interest Short interest is 12.7% of the free float (30 Oct 2026).

Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).

Relative performance

507510021 May 202621 Aug 202618 Nov 2026Peer median 112IONS 36
Six months, rebased to 100: Ionis Pharmaceuticals against the median of its 20 peers (local-currency closes).

Ionis Pharmaceuticals financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$960M$944M$705M$788M$587M
Revenue growth—+34%-10%+34%—
Gross profit$916M$915M$672M$756M$551M
EBITDA-$535M-$359M-$453M-$331M-$388M
Net income-$546M-$381M-$454M-$366M-$270M
Free cash flow-$616M-$320M-$546M-$331M-$290M
Capital expenditure$78.4M$57.1M$50.3M$28.0M$20.1M
Total debt$2.17B$2.61B$1.96B$1.97B$1.37B

Quarterly statements and history in the cockpit →

Ionis Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%-20%0%+20%0874EMCUREAJANTPHARM600566CAMXGLAXOTVTXERAS0022946000796000854536PTCT326030000100LQDADFTXMANE128940IONS6-month return →1-month return →
Up and to the right = strong over both horizons. Ionis Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%+600%+800%0×5×10×15×0874EMCUREAJANTPHARM600566CAMXGLAXOTVTX002294600079000100LQDAIONSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ionis Pharmaceuticals is the large dot.

Ionis Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (IONS vs ALNY vs PFE vs BIIB)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Ionis Pharmaceuticals IONS$4.56B-64%-1%-59%5.0×n/a
Alnylam Pharmaceuticals ALNY$20.0B-50%+56%20%3.9×0.5%
Pfizer PFE$160B+9%+1%26%3.3×-4.3%
Biogen BIIB$37.2B+34%+2%17%4.4×10.1%

How Ionis Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ionis Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
MeasureIONSPeer medianRank in peer set
1-month return-39.7%+0.7%lowest of 21
6-month return-63.5%+10.4%lowest of 21
Distance from 52-week high-68.4%-29.4%lowest of 21
Revenue growth (TTM)-0.8%+12.0%4th lowest of 18
Operating margin-58.9%15.8%lowest of 18
EV / Sales5.0×4.5×8th most expensive of 18
ROIC minus cost of capital-72.1 pp+4.9 pplowest of 16

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Ionis Pharmaceuticals IONSUnited States$4.56B-64%-1%-59%5.0×n/an/a
Guangzhou Baiyunshan Pharmaceutical 0874.HKHong Kong$4.48B-23%+6%3%0.6×1.3%+4.0%
Emcure Pharmaceuticals EMCURE.NSIndia$4.74B+37%+21%16%4.5×15.9%+12.7%
Ajanta Pharma AJANTPHARM.NSIndia$4.38B+1%+25%25%6.5×23.8%+13.8%
HUBEI JUMPCAN PHARMACEUTICAL 600566.SSChina$4.36B+12%-4%32%3.2×-9.9%+0.3%
Camurus CAMX.STSweden$4.36B+36%+3%38%16.6×7.9%+46.5%
GlaxoSmithKline Pharmaceuticals GLAXO.NSIndia$4.79B+10%+12%33%10.2×26.4%+5.5%
Travere Therapeutics TVTXUnited States$4.82B+16%+49%-3%7.6×17.3%+19.9%
Erasca ERASUnited States$4.83B+24%n/an/an/an/an/a
Shenzhen Salubris Pharmaceuticals 002294.SZChina$4.31B-24%+14%11%5.8×12.4%+9.7%
Humanwell Healthcare (Group) 600079.SSChina$4.87B+11%+2%15%1.6×-8.8%+3.0%
Beijing TongRenTang 600085.SSChina$4.91B-12%-17%8%2.2×1.7%+6.2%
Santen Pharmaceutical 4536.TJapan$4.14B+10%+2%16%2.0×-5.0%+3.2%
IPCA Laboratories IPCALAB.NSIndia$5.03B+12%+12%18%4.6×16.5%+12.2%
PTC Therapeutics PTCTUnited States$5.03B-15%-35%22%3.1×6.6%+35.4%
SKBP 326030.KSSouth Korea$5.03B-16%+37%38%6.8×-4.4%+93.6%
Yuhan 000100.KSSouth Korea$4.11B-10%+8%6%2.3×n/an/a
Liquidia LQDAUnited States$5.08B-9%+798%47%7.8×5.0%+192.5%
Definium Therapeutics DFTXUnited States$3.99B+40%n/an/an/an/an/a
Veradermics MANEUnited States$5.27B+19%n/an/an/an/an/a
HanmiPharm 128940.KSSouth Korea$3.95B-2%+14%16%3.3×4.7%+7.5%

Ionis Pharmaceuticals bonds and credit

Ionis Pharmaceuticals has 2 bonds outstanding with $1.34B face value.

Every bond, yield and spread in the cockpit →

Questions

Who are Ionis Pharmaceuticals's main competitors?
Named competitors: Alnylam Pharmaceuticals (ALNY), Pfizer (PFE), Biogen (BIIB). The cockpit's measured peer set (industry) also includes Guangzhou Baiyunshan Pharmaceutical (0874.HK), Emcure Pharmaceuticals (EMCURE.NS), Ajanta Pharma (AJANTPHARM.NS), HUBEI JUMPCAN PHARMACEUTICAL (600566.SS), Camurus (CAMX.ST), GlaxoSmithKline Pharmaceuticals (GLAXO.NS).
Is Ionis Pharmaceuticals expensive compared with its peers?
On ev / sales it trades at 5.0× against a peer median of 4.5×, 8th most expensive of 18 in its peer set.
How has Ionis Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -63.5% against +10.4% for the median peer; over one year -62.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.